ArticleCancer medicine2025

Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study.

Jung Sun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.